CC49, an antibody (mAb) reactive to tumor-associated glycoprotein (TAG-72), has been extensively studied for radioimmunotherapy for colon cancer. Myelotoxicity has been dose-limiting because of prolonged circulation time in the plasma, and human anti-mouse antibody responses were observed in the majority of patients. A CH2 domain deleted and humanized CC49 (HuCC49ΔCh2) was developed to ameliorate these problems. This study reports biodistribution and dosimetry of 111In/90Y-HuCC49ΔCh2 (IDEC-159).
Materials and Methods:
Five (5) patients with colon cancer were enrolled. Each patient received intravenous administration of 185 MBq 111In-HuCC49ΔCh2, followed by sequential gamma camera imaging, and blood counting. Uptakes and clearance half-lives for organs and tumors were quantified from images. Absorbed doses for 90Y-HuCC49ΔCh2 were derived from 111In-HuCC49ΔCh2 kinetic data.
Results:
Compared to reported 111In/90Y-CC49 data in the literature, median blood circulation T1/2β was less at 38 (31–43) hours for 90Y-HuCC49ΔCh2, than 50 hours for 90Y-CC49. Median tumor-to-marrow absorbed dose ratio was 18 for 90Y-HuCC49ΔCh2, and 9.53 for 90Y-CC49. Median tumor-to-liver absorbed dose ratio was 3.14 for 90Y-HuCC49ΔCh2, and 1.0 for 90Y-CC49. Median tumor-to-spleen absorbed dose was 3.19 for 90Y-HuCC49ΔCh2, and 1.07 for 90Y-CC49.
Conclusions:
A humanized and CH2 domain-deleted CC49 antibody radiolabeled with 111In/90Y showed improved tumor-to-normal dose ratios over those reported from studies with intact CC49.
Get full access to this article
View all access options for this article.
References
1.
DeNardoSJ, DeNardoGL, O'GradyLFet al.Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl, 1988; 3:96.
2.
PressOW, EaryJF, AppelbaumFRet al.Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med, 1993; 329:1219.
3.
KaminskiMS, ZasadnyKR, FrancisIRet al.Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med, 1993; 329:459.
MurrayJL, MaceyDJ, KasiLPet al.Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer, 1994; 73:1057.
6.
DivgiCR, ScottAM, DantisLet al.Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med, 1995; 36:586.
7.
MeredithRF, KhazaeliMB, PlottWEet al.Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin Cancer Res, 1996; 2:1811.
8.
TemperoM, LeichnerP, DalrympleGet al.High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: A phase I trial. J Clin Oncol, 1997; 15:1518.
9.
TemperoM, LeichnerP, Baranowska-KortylewiczJet al.High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: A phase I trial. Clin Cancer Res, 2000; 6:3095.
10.
Slavin-ChioriniDC, KashmiriSV, SchlomJet al.Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res, 1995; 55:5957s.
11.
KashmiriSV, ShuL, PadlanEAet al.Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma, 1995; 14:461.
12.
ForeroA, MeredithRF, KhazaeliMBet al.A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm, 2003; 18:751.
ShenS, ForeroA, MeredithRFet al.Impact of rituximab treatment on 90Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med, 2010; 51:150.
15.
ShenS, FiveashJB. Dosimetry for targeted radiotherapy, chapter 13. ReillyRM. Monoclonal Antibody and Peptide Targeted Radiotherapy of Malignancies. New York: John Wiley & Sons, Inc., 2010; 473.
16.
ShenS, ForeroA, LoBuglioAFet al.Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. J Nucl Med, 2005; 46:642.
17.
ThomasSR, MaxonHR, KereiakesJG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys, 1976; 03:253.
18.
SiegelJA, ThomasSR, StubbsJBet al.MIRD pamphlet no. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med, 1999; 40:37S.
ShenS, DeNardoGL, DeNardoSJ. Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys, 1994; 21:1409.
21.
StabinMG, SparksRB, CroweE. OLINDA/EXM: The second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 2005; 46:1023.
22.
StabinMG. MIRDOSE: Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med, 1996; 37:538.
23.
SgourosG. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med, 1993; 34:689.
24.
ShenS, DeNardoGL, SgourosGet al.Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med, 1999; 40:2102.
25.
JohnsonVG, SchlomJ, PatersonAJet al.Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3. Cancer Res, 1986; 46:850.
26.
ColcherD, MinelliMF, RoselliMet al.Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res, 1988; 48:4597.
27.
MeredithR, ShenS, MaceyDet al.Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy. Cancer Biother Radiopharm, 2003; 18:393.
28.
MurrayJL, MaceyDJ, GrantEJet al.Enhanced TAG-72 expression and tumor uptake of radiolabeled monoclonal antibody CC49 in metastatic breast cancer patients following alpha-interferon treatment. Cancer Res, 1995; 55:5925s.
29.
LeichnerPK, AkabaniG, ColcherDet al.Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49. J Nucl Med, 1997; 38:512.
30.
WhitwellJR, SpiersFW. Calculated beta-ray dose factors for trabecular bone. Phys Med Biol, 1976; 21:16.
31.
StabinMG, SiegelJA. Physical models and dose factors for use in internal dose assessment. Health Phys, 2003; 85:294.
32.
SiegelJA, YeldellD, GoldenbergDMet al.Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: Improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med, 2003; 44:67.
33.
SiegelJA. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: Practical aspects and limitations of red marrow dosimetry. Cancer Biother Radiopharm, 2005; 20:126.
34.
CarrasquilloJA, WhiteJD, PaikCHet al.Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution. J Nucl Med, 1999; 40:268.
35.
WongJY, SomloG, Odom-MaryonTet al.Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with carcinoembryonic antigen-producing metastatic breast cancer. Clin Cancer Res, 1999; 5:3224s.
36.
ShenS, DeNardoSJ, RichmanCMet al.Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry. J Nucl Med, 2005; 46:1034.
